Fig. 8
RT-qPCR quantification of total or specific CD20 splice variant expression within three different CLL sample cohorts. Quantification by RT-qPCR of total a or specific b, c CD20 splice variants in three cohorts of patients: CLL patient samples collected during routine diagnosis (50.8–49.1 %, stages A–B/C, respectively) (CHU Toulouse, France, n = 70); CD19-positive B cells purified from diagnostic stages B and C (65.5 and 34.5 %, respectively); and CLL samples from elderly patients (>65 years; median, 71.2) (CLL2007-SA trial (n = 54) or from patients with relapsed stages A, B, or C (mainly stages B and C for 88.7 %) with active disease (CLL01 BOMP clinical trial, n = 70). c Proportion (in %) of each CD20 transcript variant in different CLL cohorts. (*) and (**) are the results of X2 tests with p = 0.01 and p < 0.001, respectively, compared to PBMC samples